Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 27, 2020
Daily News
March 27, 2020
- Otsuka, NCC Develop Comprehensive Genomic Profiling Assay for Blood Cancer
March 27, 2020
- Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- Eisai Files CTCL/PTCL Drug at MHLW Request
March 27, 2020
- FPMAJ Launches Survey to Gauge COVID-19 Impact on Drug Supplies
March 27, 2020
- Yoshindo Curbs Shipments of Tranexamic Acid as Coronavirus Hits API Supplies
March 27, 2020
- Ono, BMS Submit Opdivo/Yervoy Duo for NSCLC in Combination with Chemo
March 27, 2020
- Generic Use Rate at 77.1% in October-December 2019: JGA
March 27, 2020
- ICH Vancouver Meeting Cancelled due to COVID-19 Pandemic
March 27, 2020
- Takeda to Introduce Fronteo’s Drug Discovery Support AI System
March 27, 2020
- Roche Diagnostics Files New Coronavirus Test in Japan
March 27, 2020
- Pfizer Japan Extends Voluntary Ban on Doctor Visits to April 10
March 27, 2020
- Otsuka’s PDE4 Inhibitor Difamilast Delivers Positive Data for Atopic Dermatitis in Japan PIII
March 27, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…